Abstract
Background: Retention and compliance are hurdles in many clinical trials designed for adolescents. Factors that may improve these issues in a challenging population may lead to increased data and power in much needed adolescent substance abuse research.
Methods: Within a large-scale smoking cessation study for adolescents, physician continuity (PC) was examined to determine its effect on retention, compliance, and cessation.
Results: In an analysis of 98 participants, participants with physician continuity throughout the study were more likely to attend more treatment visits and be medication compliant. It was also found that PC had no effect on participant smoking cessation.
Conclusions: It appears that PC may be one way to increase retention and compliance within an adolescent clinical trial, without interfering with the specific aim of the research study (in this case, smoking cessation).
Keywords: Adolescent research, substance use, compliance.
Adolescent Psychiatry
Title:Does Physician Continuity Within a Clinical Trial Increase Retention and Compliance Among Adolescent Smokers?
Volume: 3 Issue: 2
Author(s): A. Lee Lewis, Nathaniel Baker, Matthew Carpenter, Erin Klintworth and Kevin M. Gray
Affiliation:
Keywords: Adolescent research, substance use, compliance.
Abstract: Background: Retention and compliance are hurdles in many clinical trials designed for adolescents. Factors that may improve these issues in a challenging population may lead to increased data and power in much needed adolescent substance abuse research.
Methods: Within a large-scale smoking cessation study for adolescents, physician continuity (PC) was examined to determine its effect on retention, compliance, and cessation.
Results: In an analysis of 98 participants, participants with physician continuity throughout the study were more likely to attend more treatment visits and be medication compliant. It was also found that PC had no effect on participant smoking cessation.
Conclusions: It appears that PC may be one way to increase retention and compliance within an adolescent clinical trial, without interfering with the specific aim of the research study (in this case, smoking cessation).
Export Options
About this article
Cite this article as:
Lewis A. Lee, Baker Nathaniel, Carpenter Matthew, Klintworth Erin and M. Gray Kevin, Does Physician Continuity Within a Clinical Trial Increase Retention and Compliance Among Adolescent Smokers?, Adolescent Psychiatry 2013; 3 (2) . https://dx.doi.org/10.2174/2210676611303020011
DOI https://dx.doi.org/10.2174/2210676611303020011 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Target Enzyme in Alzheimer’s Disease: Acetylcholinesterase Inhibitors
Current Topics in Medicinal Chemistry Conformational Changes Preceding Amyloid-Fibril Formation of Amyloid- Beta, Prion Protein and Stefin B; Parallels in pH Dependence
Medicinal Chemistry Reviews - Online (Discontinued) Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Approaches to Enantiomerically Pure 3,4-Dihydro-2H-1-Benzopyran-3-Amines
Current Organic Chemistry Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Pharmacophore Based 3D-QSAR Modeling and Molecular Docking of Leucettines as Potent Dyrk1A Inhibitors
Letters in Drug Design & Discovery Design, Synthesis and In Vitro Biological Evaluation of 3- styrylbenzimidamides as Potential BACE1 Inhibitors
Letters in Drug Design & Discovery Threshold-Independent Meta-Analysis of Alzheimer`s Disease Transcriptomes shows Progressive Changes in Hippocampal Functions, Epigenetics and microRNA Regulation
Current Alzheimer Research The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Brain Norepinephrine System as a Target for Antidepressant and Mood Stabilizing Medications
Current Drug Targets Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Neurotoxicity of Ecstasy (MDMA): An Overview
Current Pharmaceutical Biotechnology Health Consequences of Catabolic Synthesis of Hippuric Acid in Humans
Current Clinical Pharmacology CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
Current Alzheimer Research The Effects of Psychological Stress on Depression
Current Neuropharmacology Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine
Current Pharmaceutical Design Denouement of Chemicals on Amyotrophic Lateral Sclerosis: Is Green Chemistry the Answer
Medicinal Chemistry May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
Clinical Cancer Drugs